$ELOX
Eloxx Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041837 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.387M $1.802M
YoY Change 5.53% -31.87%
% of Gross Profit
Research & Development $1.250M $2.338M
YoY Change -74.39% -69.44%
% of Gross Profit
Depreciation & Amortization $13.00K $12.00K
YoY Change -43.48% -45.45%
% of Gross Profit
Operating Expenses $3.637M $4.140M
YoY Change -49.08% -59.79%
Operating Profit -$3.637M -$4.140M
YoY Change -49.08% -59.79%
Interest Expense -$238.0K -$209.0K
YoY Change -34.97% -35.09%
% of Operating Profit
Other Income/Expense, Net $45.00K -$201.0K
YoY Change -112.3% -37.58%
Pretax Income -$3.592M -$4.341M
YoY Change -52.16% -59.12%
Income Tax
% Of Pretax Income
Net Earnings -$3.592M -$4.341M
YoY Change -52.16% -59.12%
Net Earnings / Revenue
Basic Earnings Per Share -$1.31 -$1.96
Diluted Earnings Per Share -$1.31 -$1.96
COMMON SHARES
Basic Shares Outstanding 2.753M 2.166M
Diluted Shares Outstanding 2.748M 2.212M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.775M $4.331M
YoY Change -80.55% -85.59%
Cash & Equivalents $4.775M $4.331M
Short-Term Investments
Other Short-Term Assets $854.0K $1.051M
YoY Change -23.55% -31.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.629M $5.382M
YoY Change -78.07% -82.96%
LONG-TERM ASSETS
Property, Plant & Equipment $107.0K $130.0K
YoY Change -50.23% -31.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $413.0K $611.0K
YoY Change -65.81% -54.71%
TOTAL ASSETS
Total Short-Term Assets $5.629M $5.382M
Total Long-Term Assets $413.0K $611.0K
Total Assets $6.042M $5.993M
YoY Change -77.52% -81.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.134M $3.121M
YoY Change 96.49% 61.38%
Accrued Expenses $2.442M $2.752M
YoY Change -45.95% -43.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.819M $2.276M
YoY Change 11.42% 102.31%
Total Short-Term Liabilities $23.47M $21.25M
YoY Change 8.24% 8.96%
LONG-TERM LIABILITIES
Long-Term Debt $2.621M $3.334M
YoY Change -73.43% -70.04%
Other Long-Term Liabilities $3.000K $4.000K
YoY Change -99.06% -99.19%
Total Long-Term Liabilities $2.621M $3.334M
YoY Change -73.43% -70.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.47M $21.25M
Total Long-Term Liabilities $2.621M $3.334M
Total Liabilities $26.09M $24.59M
YoY Change -18.11% -21.01%
SHAREHOLDERS EQUITY
Retained Earnings -$288.6M -$285.0M
YoY Change 7.65% 9.36%
Common Stock $268.5M $266.4M
YoY Change 1.22% 0.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.05M -$18.60M
YoY Change
Total Liabilities & Shareholders Equity $6.042M $5.993M
YoY Change -77.52% -81.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.592M -$4.341M
YoY Change -52.16% -59.12%
Depreciation, Depletion And Amortization $13.00K $12.00K
YoY Change -43.48% -45.45%
Cash From Operating Activities -$3.450M -$2.066M
YoY Change -50.33% -78.8%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $233.0K $14.00K
YoY Change
Cash From Investing Activities $233.0K $14.00K
YoY Change -585.42% -300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.670M 1.428M
YoY Change 144.67%
NET CHANGE
Cash From Operating Activities -3.450M -2.066M
Cash From Investing Activities 233.0K 14.00K
Cash From Financing Activities 3.670M 1.428M
Net Change In Cash 453.0K -624.0K
YoY Change -108.25% -93.6%
FREE CASH FLOW
Cash From Operating Activities -$3.450M -$2.066M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.450M -$2.066M
YoY Change -49.99% -78.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31326
dei Entity Registrant Name
EntityRegistrantName
ELOXX PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
577-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
ELOX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2752774
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4331000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19207000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
210000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
261000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
841000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
5382000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20129000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
130000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
481000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
825000
CY2023Q2 us-gaap Assets
Assets
5993000
CY2022Q4 us-gaap Assets
Assets
21123000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3121000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3020000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2752000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2799000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2276000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3980000
CY2023Q2 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
12535000
CY2022Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
12535000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
492000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
75000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
45000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21251000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23091000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3334000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8557000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
135000
CY2023Q2 us-gaap Liabilities
Liabilities
24589000
CY2022Q4 us-gaap Liabilities
Liabilities
31783000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2492666
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2492666
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2166356
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2166356
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
25000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
266379000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263706000
CY2023Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
41000
us-gaap Share Based Compensation
ShareBasedCompensation
1207000
CY2022Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
0
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-284959000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274388000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-18596000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10660000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5993000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21123000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2338000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7651000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5826000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15550000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1802000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2645000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3797000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5699000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4140000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
10296000
us-gaap Operating Expenses
OperatingExpenses
9623000
us-gaap Operating Expenses
OperatingExpenses
21249000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4140000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10296000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9623000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21249000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-201000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-322000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-948000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-989000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4341000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
us-gaap Net Income Loss
NetIncomeLoss
-10571000
us-gaap Net Income Loss
NetIncomeLoss
-22238000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.27
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2212364
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2212364
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166352
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166352
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2189487
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2189487
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166314
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166314
us-gaap Profit Loss
ProfitLoss
-10571000
us-gaap Profit Loss
ProfitLoss
-22238000
us-gaap Share Based Compensation
ShareBasedCompensation
1666000
us-gaap Depreciation
Depreciation
27000
us-gaap Depreciation
Depreciation
44000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
344000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
284000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
167000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
258000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
30000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
166000
elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
406000
elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
13000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
180000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
368000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
101000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
555000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-47000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
674000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-351000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-279000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8880000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19238000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
25000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1428000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7500000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
0
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
7000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6072000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14927000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12256000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19468000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42567000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4541000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30311000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4331000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30048000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
210000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
263000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4541000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2752000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30311000
us-gaap Interest Paid Net
InterestPaidNet
632000
us-gaap Interest Paid Net
InterestPaidNet
620000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
597000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6230000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
16293000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
228000
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1428000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
610000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4341000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-18596000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11686000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1812000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-285000000.0
CY2023Q2 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
4300000
us-gaap Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
1700000
us-gaap Derivative Cash Received On Hedge
DerivativeCashReceivedOnHedge
200000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2799000
CY2022Q4 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.1375
CY2023Q2 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
276000
CY2022Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
366000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
458000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
93000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
107000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
202000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
841000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661000
CY2023Q2 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2079000
CY2022Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1544000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
139000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
750000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
234000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2023Q2 elox Accrued Interest On Debt
AccruedInterestOnDebt
63000
CY2022Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
146000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
237000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
134000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
906000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2988000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1106000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
209000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
4791000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2276000
CY2023Q2 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-819000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3334000
elox Royalties Percentage Of Net Sales Based On Actual Amount Of Funding
RoyaltiesPercentageOfNetSalesBasedOnActualAmountOfFunding
0.06
CY2023Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
41000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
249403
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
105.87
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
195895
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20276
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.47
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
425022
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
62.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
121432
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
160.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M19D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
610
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
744
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1207
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1666
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
230000
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
454000
us-gaap Interest Expense Other
InterestExpenseOther
715000
us-gaap Interest Expense Other
InterestExpenseOther
878000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
57000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
23000
us-gaap Interest And Other Income
InterestAndOtherIncome
225000
us-gaap Interest And Other Income
InterestAndOtherIncome
25000
CY2023Q2 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2022Q2 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
406000
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-19000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
CY2023Q2 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
17000
CY2022Q2 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-104000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
30000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
166000
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
-3000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
28000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-201000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-322000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-948000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-989000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4341000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
us-gaap Net Income Loss
NetIncomeLoss
-10571000
us-gaap Net Income Loss
NetIncomeLoss
-22238000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2212364
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2212364
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166352
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166352
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2189487
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2189487
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166314
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166314
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.27
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
426043
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
271308

Files In Submission

Name View Source Status
0000950170-23-041837-index-headers.html Edgar Link pending
0000950170-23-041837-index.html Edgar Link pending
0000950170-23-041837.txt Edgar Link pending
0000950170-23-041837-xbrl.zip Edgar Link pending
elox-20230630.htm Edgar Link pending
elox-20230630.xsd Edgar Link pending
elox-ex31_1.htm Edgar Link pending
elox-ex31_2.htm Edgar Link pending
elox-ex32_1.htm Edgar Link pending
elox-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
elox-20230630_cal.xml Edgar Link unprocessable
elox-20230630_def.xml Edgar Link unprocessable
elox-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elox-20230630_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
elox-20230630_lab.xml Edgar Link unprocessable